Metformin (MET) for the prevention of Alpelisib (ALP)-related Hyperglycemia (HG) in PIK3CA-mutated, Hormone Receptor-Positive (HR[+]) HER2-Negative (HER2[-]) Advanced Breast Cancer (ABC): The METALLICA study

被引：9
|
作者：
Borrego, Manuel Ruiz
Tolosa, Pablo
Blanch, Salvador
Fernandez, Adela
Urriticoechea, Ander
Blancas, Isabel
Saura, Cristina
Rojas, Beatriz
Bermejo, Begona
Ponce, Jose
Gion, Maria
Llabres, Elisenda
Galve, Elena
Cueva, Juan Fernando
Lopez, Ana
Alonso-Romero, Jose L.
Gonzalez-Santiago, Santiago
De Duenas, Eduardo Martinez
Peralta, Fernando Gomez
Ciruelos, Eva
Perez-Garcia, Jose Manuel
Llombart-Cussac, Antonio
Cortes, Javier
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 05期
关键词：
D O I：
10.1158/1538-7445.SABCS22-PD8-02
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PD8-02
引用
收藏
页数：3
相关论文
共 50 条
  • [11] Treatment of Advanced Hormone Receptor-Positive (HR+) HER2-negative Breast Cancer
    Ditsch, Nina
    Schmidt, Marcus
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2019, 79 (12) : 1328 - 1335
  • [12] Alpelisib Efficacy in Hormone Receptor-Positive HER2-Negative PIK3CA-Mutant Advanced Breast Cancer Post-Everolimus Treatment
    Raphael, Ari
    Salmon-Divon, Mali
    Epstein, Jessica
    Zahavi, Tamar
    Sonnenblick, Amir
    Shachar, Shlomit S.
    GENES, 2022, 13 (10)
  • [13] BioItaLEE: Molecular features of postmenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2-) PIK3CA-mutated advanced breast cancer (ABC) on first-line treatment with ribociclib plus letrozole and on second-line treatment with alpelisib plus fulvestrant
    Allegrini, G.
    Orditura, M.
    Del Mastro, L.
    Zamagni, C.
    Torrisi, R.
    Guarneri, V.
    Paris, I.
    Sarobba, G.
    Puglisi, F.
    Colleoni, M. A.
    Montemurro, F.
    Zambelli, A.
    Cazzaniga, M. E.
    Valerio, M. R.
    Bianchi, G.
    Romagnoli, E.
    Caruso, M.
    Cinieri, S.
    Castelletti, D.
    Arpino, G.
    ANNALS OF ONCOLOGY, 2020, 31 : S302 - S302
  • [14] EPIK-B4: A phase 2, randomized study of metformin (MET) extended release (XR) plus /dapagliflozin (DAPA) to prevent hyperglycemia (HG) in patients (pts) with hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-), PIK3CA-mutated (mut) advanced breast cancer (ABC) treated with alpelisib (ALP) and fulvestrant (FUL).
    Gradishar, William John
    Farooki, Azeez
    Giridhar, Karthik
    Moore, Heather
    Johnston, Abigail
    Miller, Michelle Kristine
    Wang, Craig
    Reising, Albert
    O'Shaughnessy, Joyce
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [15] Alpelisib (ALP) plus endocrine therapy (ET) in patients (pts) with PIK3CA-mutated, hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2e) advanced breast cancer (ABC): Subgroup analyses from the BYLieve study
    Cardoso, F.
    Juric, D.
    Lerebours, F.
    Krop, I.
    Borrego, M. Ruiz
    Neven, P.
    Park, Y. H.
    Yardley, D.
    Jhaveri, K.
    Arce, C.
    Gu, E.
    Akdere, M.
    Rugo, H. S.
    ANNALS OF ONCOLOGY, 2022, 33 : S206 - S207
  • [16] Alpelisib (ALP) plus endocrine therapy (ET) in patients (pts) with PIK3CA-mutated hormone receptor-positive (HR plus ), human epidermal growth factor-2-negative (HER2-) advanced breast cancer (ABC): First interim BYLieve study results.
    Rugo, Hope S.
    Borrego, Manuel Ruiz
    Chia, Stephen K. L.
    Juric, Dejan
    Turner, Nicholas C.
    Drullinsky, Pamela
    Lerebours, Florence
    Bianchi, Giulia Valeria
    Nienstedt, Carolyn C.
    Ridolfi, Antonia
    Thuerigen, Astrid
    Ciruelos, Eva
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [17] A phase I/Ib study of inavolisib (GDC-0077) in combination with fulvestrant in patients (pts) with PIK3CA-mutated hormone receptor-positive/HER2-negative (HR+/HER2-) metastatic breast cancer
    Juric, Dejan
    Bedard, Phillippe L.
    Cervantes, Andres
    Gambardella, Valentina
    Oliveira, Mafalda
    Saura, Cristina
    Kalinsky, Kevin M.
    Hamilton, Erika
    Italiano, Antoine
    Krop, Ian E.
    Schmid, Peter
    Turner, Nicholas C.
    Varga, Andrea
    Royer-Joo, Stephanie
    Hutchinson, Katherine E.
    Schutzman, Jennifer L.
    Jhaveri, Komal L.
    CANCER RESEARCH, 2022, 82 (04)
  • [18] Alpelisib and fulvestrant in PIK3CA-mutated hormone receptor-positive HER2-negative advanced breast cancer included in the French early access program (Jan, 10.1038/s41388-022-02585-3, 2023)
    Bello Roufai, D.
    Goncalves, A.
    de la Motte Rouge, T.
    Akla, S.
    Blonz, C.
    Grenier, J.
    Gligorov, J.
    Saghatchian, M.
    Bailleux, C.
    Simon, H.
    Desmoulins, I.
    Tharin, Z.
    Renaud, E.
    Bertho, M.
    Benderra, M-a
    Delaloge, S.
    Robert, L.
    Cottu, P.
    Pierga, J. Y.
    Loirat, D.
    Bertucci, A.
    Renouf, B.
    Bidard, F. C.
    Lerebours, F.
    ONCOGENE, 2023, 42 (17) : 1417 - 1417
  • [19] INAVO121: Phase III study of inavolisib (INAVO) plus fulvestrant (FUL) vs. alpelisib (ALP) plus FUL in patients (pts) with hormone receptor-positive, HER2-negative (HR+, HER2-) PIK3CA-mutated (mut) locally advanced or metastatic breast cancer (LA/mBC)
    Juric, Dejan
    Kalinsky, Kevin
    Im, Seock-Ah
    Ciruelos, Eva M.
    Bianchini, Giampaolo
    Barrios, Carlos H.
    Jacot, William
    Schmid, Peter
    Loi, Sherene
    Rugo, Hope S.
    Craine, Veronica
    Hutchinson, Katherine E.
    Flechais, Aulde
    Thanopoulou, Eirini
    Harbeck, Nadia
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [20] INAVO121: Phase III study of inavolisib (INAVO) plus fulvestrant (FUL) vs. alpelisib (ALP) plus FUL in patients (pts) with hormone receptor-positive, HER2-negative (HR+, HER2-), PIK3CA-mutated (mut) locally advanced or metastatic breast cancer (LA/mBC)
    Juric, Dejan
    Kalinsky, Kevin
    Im, Seock-Ah
    Ciruelos, Eva
    Bianchini, Giampaolo
    Barrios, Carlos H., Sr.
    Jacot, William
    Schmid, Peter
    Loi, Sherene
    Rugo, Hope S.
    Craine, Veronica
    Hutchinson, Katherine E.
    Flechais, Aulde
    Thanopoulou, Eirini
    Harbeck, Nadia
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
12345